|
|
Vaccine Detail
|
Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes |
| Vaccine Information |
- Vaccine Name: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tumor-specific antigen (NCT01759810)
- Immunization Route: Intramuscular injection (i.m.)
- Description: Tumor cells and tumor stem cells are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Autologous haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells. (NCT01759810)
|
| Host Response |
|
|
| References |
NCT01759810: Proteome-based Personalized Immunotherapy of Glioblastoma [https://clinicaltrials.gov/study/NCT01759810]
|
|
